JP2022501065A5 - - Google Patents
Info
- Publication number
- JP2022501065A5 JP2022501065A5 JP2021539334A JP2021539334A JP2022501065A5 JP 2022501065 A5 JP2022501065 A5 JP 2022501065A5 JP 2021539334 A JP2021539334 A JP 2021539334A JP 2021539334 A JP2021539334 A JP 2021539334A JP 2022501065 A5 JP2022501065 A5 JP 2022501065A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024127876A JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732329P | 2018-09-17 | 2018-09-17 | |
| US62/732,329 | 2018-09-17 | ||
| PCT/US2019/050110 WO2020060781A1 (en) | 2018-09-17 | 2019-09-06 | Anti-klrg1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024127876A Division JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501065A JP2022501065A (ja) | 2022-01-06 |
| JP2022501065A5 true JP2022501065A5 (enExample) | 2022-09-14 |
| JP7654548B2 JP7654548B2 (ja) | 2025-04-01 |
Family
ID=69887899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539334A Active JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
| JP2024127876A Pending JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024127876A Pending JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12365735B2 (enExample) |
| EP (1) | EP3852779A4 (enExample) |
| JP (2) | JP7654548B2 (enExample) |
| KR (1) | KR102934267B1 (enExample) |
| CN (2) | CN112752580B (enExample) |
| AU (1) | AU2019344524B2 (enExample) |
| BR (1) | BR112021004553A2 (enExample) |
| CA (1) | CA3113069A1 (enExample) |
| EA (1) | EA202190647A1 (enExample) |
| IL (2) | IL281594B2 (enExample) |
| MX (2) | MX2021003119A (enExample) |
| SG (1) | SG11202102114UA (enExample) |
| WO (1) | WO2020060781A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3852779A4 (en) | 2018-09-17 | 2022-06-08 | Abcuro, Inc. | ANTI-KLRG1 ANTIBODIES |
| US20230331853A1 (en) * | 2020-09-11 | 2023-10-19 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
| CA3212311A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| US20260103525A1 (en) * | 2022-09-27 | 2026-04-16 | The Brigham And Women's Hospital, Inc. | Klrg1 signalling therapy for infectious disease |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2595169A1 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| CA2673870A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| WO2011016238A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| EP2611832B1 (en) * | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| EP2699256B1 (en) | 2011-04-21 | 2017-09-27 | The Regents of the University of Colorado, a body corporate | Compositions and methods for the treatment of neuromyelitis optica |
| ES2929575T3 (es) | 2011-06-06 | 2022-11-30 | Novo Nordisk As | Anticuerpos terapéuticos |
| JPWO2012176765A1 (ja) * | 2011-06-24 | 2015-02-23 | 株式会社ペルセウスプロテオミクス | 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体 |
| CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| TW201622743A (zh) | 2014-03-19 | 2016-07-01 | 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 | 免疫原醣肽、包含該醣肽之組合物及其用途 |
| WO2016009487A1 (ja) | 2014-07-14 | 2016-01-21 | 三菱電機株式会社 | 空気調和装置 |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| PE20181349A1 (es) | 2015-10-07 | 2018-08-22 | Hoffmann La Roche | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| JP7023853B2 (ja) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗ｔｒｅｍ１抗体及びその使用方法 |
| CA3026182A1 (en) | 2016-06-03 | 2017-12-07 | Steven Greenberg | Klrg1 signaling therapy |
| AU2017326003A1 (en) | 2016-09-16 | 2019-04-11 | Children's Medical Center Corporation | KLRG1 depletion therapy |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| WO2018237341A1 (en) | 2017-06-22 | 2018-12-27 | Development Center For Biotechnology | A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY |
| US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
| EP3852779A4 (en) | 2018-09-17 | 2022-06-08 | Abcuro, Inc. | ANTI-KLRG1 ANTIBODIES |
| MX2021012171A (es) | 2019-04-09 | 2021-12-10 | Abcuro Inc | Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1). |
| CA3212311A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
-
2019
- 2019-09-06 EP EP19862063.5A patent/EP3852779A4/en active Pending
- 2019-09-06 AU AU2019344524A patent/AU2019344524B2/en active Active
- 2019-09-06 CA CA3113069A patent/CA3113069A1/en active Pending
- 2019-09-06 KR KR1020217008068A patent/KR102934267B1/ko active Active
- 2019-09-06 EA EA202190647A patent/EA202190647A1/ru unknown
- 2019-09-06 IL IL281594A patent/IL281594B2/en unknown
- 2019-09-06 CN CN201980060735.4A patent/CN112752580B/zh active Active
- 2019-09-06 CN CN202411978380.6A patent/CN119638835A/zh active Pending
- 2019-09-06 BR BR112021004553-8A patent/BR112021004553A2/pt unknown
- 2019-09-06 SG SG11202102114UA patent/SG11202102114UA/en unknown
- 2019-09-06 US US17/285,793 patent/US12365735B2/en active Active
- 2019-09-06 MX MX2021003119A patent/MX2021003119A/es unknown
- 2019-09-06 WO PCT/US2019/050110 patent/WO2020060781A1/en not_active Ceased
- 2019-09-06 JP JP2021539334A patent/JP7654548B2/ja active Active
-
2021
- 2021-03-16 MX MX2025008993A patent/MX2025008993A/es unknown
-
2024
- 2024-08-02 JP JP2024127876A patent/JP2024156878A/ja active Pending
-
2025
- 2025-06-10 US US19/233,441 patent/US20260125479A1/en active Pending
- 2025-09-04 IL IL323170A patent/IL323170A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220340676A1 (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| US11578131B2 (en) | Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules | |
| CA3222764A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| JP2023539245A5 (enExample) | ||
| JP2022008382A5 (enExample) | ||
| JP2022512234A5 (enExample) | ||
| CN113817066A (zh) | 自然杀伤细胞接合抗体融合构建体 | |
| JP2020511947A5 (enExample) | ||
| JP2022504802A5 (enExample) | ||
| JP2022506719A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| HRP20191083T1 (hr) | Molekule antitijela za tim-3 i njihove upotrebe | |
| JP2018533371A5 (enExample) | ||
| JP2010524435A5 (enExample) | ||
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| JP2018510617A5 (enExample) | ||
| JP2020519308A5 (enExample) | ||
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| US20220306760A1 (en) | Igm glycovariants | |
| JP2016507523A5 (enExample) | ||
| JP2019530431A5 (enExample) | ||
| RS60920B1 (sr) | Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula | |
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 |